UBE2V1P16

Across TCGA pan-cancer cohorts, UBE2V1P16 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated UBE2V1P16 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher UBE2V1P16 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2V1P16 expression acts as an unfavorable survival marker.

KIRC, PAAD, and HNSC are the cancer types where UBE2V1P16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Tertile	II,III,IV	0.198	0.700	<.001	144	view →
PAAD	OS	Tertile	All	0.112	0.640	.004	36	view →
HNSC	DFS	Tertile	III,IV	0.050	0.611	<.001	36	view →
UCEC	OS	Tertile	All	0.593	0.879	<.001	36	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	18	view →
COAD	OS	Tertile	III,IV	0.157	0.791	.001	18	view →
OV	OS	Tertile	III,IV	0.563	0.687	.033	18	view →
GBM	DFS	Tertile	All	0.061	0.288	<.001	9	view →
LGG	OS	Tertile	All	0.607	0.889	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

UBE2V1P16–KIRC (OS)

Open the KIRC breakdown →